This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) Files for Rinvoq in Atopic Dermatitis in US & EU
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Rinvoq ??? atopic dermatitis. The drug is already marketed to treat rheumatoid arthritis.
Merck's Keytruda Gets FDA Nod for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA approves Merck's (MRK) Keytruda for the treatment of adult patients with relapsed or refractory cHL who progress after frontline therapy.
Top Research Reports for Novartis, Zoom Video & FIS
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), Zoom Video Communications (ZM) and Fidelity National Information Services (FIS).
Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates
by Zacks Equity Research
Regeneron (REGN) and Gilead (GILD) continue to be in the spotlight on coronavirus-related updates.
Amgen Down on Unsatisfactory Heart Failure Drug Study Results
by Zacks Equity Research
Amgen (AMGN) with partners post top-line data from the phase III GALACTIC-HF study on omecamtiv mecarbil, which is being evaluated for heart failure with reduced ejection fraction. Stock falls.
Signs That Your Trading Will Ruin Your Retirement - October 08, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
The Zacks Analyst Blog Highlights: Amgen, Exxon Mobil, S&P Global, HSBC and LULU
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Exxon Mobil, S&P Global, HSBC and LULU
Stock Market News for Oct 6, 2020
by Zacks Equity Research
Benchmarks closed higher on Monday as markets cheered news of President Trump???s positive response to Covid-19 treatment, and discharge from hospital.
Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Simple Secrets Anyone Can Use to Reach Early Retirement - October 05, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Top Stock Reports for Amgen, Exxon Mobil & S&P Global
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Exxon Mobil (XOM) and S&P Global (SPGI).
Merck Banks on Keytruda, Pipeline & Deals Amid Generic Woes
by Zacks Equity Research
Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.
J&J Simponi Aria Gets FDA Nod for Pediatric Use in Arthritis
by Zacks Equity Research
FDA approves J&J's (JNJ) Simponi Aria for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA) in patients two years of age and older.
The Extreme Risks of Trading Your Own Retirement Assets - September 30, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Simple Secrets Anyone Can Use to Reach Early Retirement - September 25, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
How Trading Your Own Retirement Can Fleece Your Financial Future - September 22, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch
by Ritujay Ghosh
Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies
by Zacks Equity Research
Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.
The Extreme Risks of Trading Your Own Retirement Assets - September 14, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
J&J Seeks Label Expansion of Darzalex Faspro for Amyloidosis
by Zacks Equity Research
J&J (JNJ) files sBLA to the FDA for expanding the label of Darzalex Faspro to treat patients with light chain amyloidosis. Currently, there are no approved therapies for the disease.
Easy Investing Secrets to an Early Retirement - September 09, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.